Mr. Allen Davidoff reports

XORTX ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY

XORTX Therapeutics Inc. has received notification from the Nasdaq Stock Market LLC listing qualifications department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the company's common shares listed on Nasdaq was below $1 (U.S.) for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of $1 (U.S.) per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below $1 (U.S.) for a period of 30 consecutive business days.

These notifications do not impact the company's listing on the Nasdaq Capital Market at this time. In accordance with listing Rule 5810(c)(3)(A), the company has a period of 180 calendar days from the date of notification to regain compliance with the minimum bid price requirement, during which time the shares will continue to trade on the Nasdaq Capital Market. If, at any time before the 180-calendar-day period, the bid price of the shares closes at or above $1 (U.S.) per share for a minimum of 10 consecutive business days (subject to Nasdaq's discretion to extend this 10-day period under Rule 5810(c)(3)(H)), and the company continues to meet the other listing requirements, Nasdaq will provide written notification that the company has achieved compliance with the minimum bid price requirement and will consider such deficiency matters closed.

The company is also listed on the TSX Venture Exchange, and the notification letter does not affect the company's compliance status with such listing.

The company intends to evaluate all available options to resolve the deficiency and regain compliance with Nasdaq Rule 5550(a)(2).

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: (1) its lead program XRx-026 program for the treatment of gout; (2) its XRx-008 program for ADPKD; and (3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical-stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, it is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

We seek Safe Harbor.